Evidence map›Paper›PMID 41854805›Full record

ArticleInternational journal of hematology2026

Cord blood versus matched related donor transplantation in AML not in remission: role of pre-engraftment immune reactions.

Tatsuro Hirao, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi and 5 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tatsuro HiraoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
Hisashi YamamotoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan. hhhisashi@gmail.com.ORCID http://orcid.org/0000-0003-1687-7029
Mika KunoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
Otoya WatanabeDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
Kyosuke YamaguchiDepartment of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Kosei KageyamaDepartment of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Daisuke KajiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
Yuki TayaDepartment of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Aya NishidaDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
Shinsuke TakagiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
Yuki Asano-MoriCentre for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan.
Go YamamotoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
Atsushi WakeCentre for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan.
Shuichi TaniguchiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.
Naoyuki UchidaDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although HLA-matched related donor transplantation (MRDT) is considered the preferred graft source when available, cord blood transplantation (CBT) is an alternative source, with several studies suggesting a potent graft-versus-leukemia effect. We compared outcomes between CBT and MRDT in acute myeloid leukemia (AML) not in remission and examined how pre-engraftment immune reaction (PIR), graft-versus-host disease (GVHD), and HLA mismatch affect CBT outcomes. We retrospectively analyzed 334 patients with AML not in remission who underwent first allo-HSCT using either single-unit CBT (n = 309) or MRDT (n = 25). At 5 years, CBT recipients showed significantly better leukemia-free survival (LFS) (42.0% vs. 17.6%) and lower relapse rates (24.6% vs. 54.0%), with no difference in NRM. Among CBT recipients, patients who developed mild PIR had a lower relapse rate compared with those without PIR (hazard ratio [HR], 0.48). In contrast, severe PIR was associated with higher NRM (HR, 3.13) and worse overall survival (HR, 2.12). Acute GVHD, chronic GVHD, and HLA disparity were not significantly associated with relapse. CBT was associated with superior LFS compared with MRDT in patients with AML not in remission, and PIR occurrence and severity were associated with CBT outcomes.

Indexed as

Cord Blood Stem Cell TransplantationGraft vs Leukemia EffectLeukemia, Myeloid, AcuteAdolescentAdultFemaleGraft vs Host DiseaseHistocompatibilityHistocompatibility TestingHLA AntigensHumansMaleMiddle AgedRecurrenceRemission InductionRetrospective StudiesHLA AntigensAcute myeloid leukemiaCord blood transplantationGraft-versus-leukemia effectPre-engraftment immune reaction

Identifiers

PMID41854805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.